



IMPORTANT MEDICINE SAFETY INFORMATION

11 April 2019

Dear Healthcare Professional

Re: Actemra® (tocilizumab): A New Important Identified Risk: Hepatotoxicity

Roche Products (Pty) Ltd, (F. Hoffmann-La Roche) in agreement with the Namibian Medicines Regulatory Council would like to inform you of the following:

Summary

Serious drug-induced liver injury, including acute liver failure, hepatitis and jaundice, in some cases requiring liver transplant, have been observed with the administration of Actemra® (tocilizumab). The frequency of serious hepatotoxicity is considered rare.

The currently approved prescribing information does not recommend treatment with tocilizumab in patients with elevated alanine aminotransferase (ALT) or aspartate aminotransferase (AST) above 5x upper limit of normal (ULN). Caution should continue to be exercised when considering initiation of tocilizumab treatment in patients with ALT or AST above 1,5x ULN.

In patients with Rheumatoid Arthritis (RA), Polyarticular Juvenile Idiopathic Arthritis (pJIA) and Systemic Juvenile Idiopathic Arthritis (sJIA), ALT and AST should now be monitored every 4 to 8 weeks for the first 6 months of treatment followed by every 12 weeks thereafter.

Recommended dose modifications (reduction, interruption or discontinuation) of tocilizumab due to liver enzyme abnormalities remain unchanged, refer to the guidance in the approved professional information.

Background on the safety concern

Tocilizumab is indicated for treatment of:

Rheumatoid Arthritis (RA) [IV and SC formulations]

Polyarticular Juvenile Idiopathic Arthritis (pJIA) [IV formulation] in patients 2 years of age and older.

Systemic Juvenile Idiopathic Arthritis (sJIA) [IV formulation] patients 2 years of age and older.

Tocilizumab is known to cause transient or intermittent mild to moderate elevation of hepatic transaminases and, in particular with increased frequency when used in combination with potentially hepatotoxic drugs (e.g. methotrexate). A cumulative, comprehensive assessment of serious hepatic injury including hepatic failure reported with tocilizumab was performed across all available clinical and post marketing data sources including data from FDA Adverse Event Reporting System (FAERS) and Eudravigilance (EV) databases and from the literature.

The Marketing Authorization Holder (MAH) has identified eight cases of tocilizumab related moderate to severe drug-induced liver injury including acute liver failure, hepatitis and jaundice. These events occurred between 2 weeks to more than 5 years after initiation of tocilizumab with median latency of 98 days. In these eight cases, two cases of acute liver

Roche Products (Pty) Ltd

Reg. No. 1947/027044/07

Directors: R. Ferraro (Swiss) D. Gibbons B.P. Xiphu F.M. Masilo

Company Secretary: M. Maistry

P O Box 55922 Northlands 2116

Gauteng South Africa

Tel: +27-11-502-5000

Fax: +27-11-268-5748



failure required liver transplantation. In the context of total world-wide tocilizumab exposure of approximately 1,066,849 patients (882,370.3PY) up to 10th April 2018, these events are considered rare and the benefit-risk profile of tocilizumab in the approved indications remains favorable.

To ensure adequate safety monitoring given this newly identified important risk, in RA, GCA, pJIA and sJIA patients, ALT and AST should now be monitored every 4 to 8 weeks for the first 6 months of treatment followed by every 12 weeks thereafter.

Roche is working closely with health authorities to update the product label to reflect this identified risk of hepatotoxicity and to extend the frequency of monitoring of hepatic transaminases to sJIA and pJIA indications. Healthcare Professionals should follow the guidance including dose modification and tocilizumab discontinuation as per the approved label.

Call for reporting

Healthcare Professionals should report any adverse events suspected to be associated with the use of Actemra[®] (tocilizumab) to:

Company	Contact details
Roche Products (Pty) Ltd	Drug Safety Unit Tel: +27 11 502 5009 Fax: +27 11 268 5748 email: sa_ssa.drugsafety@roche.com
Therapeutics Information and Pharmacovigilance Centre (TIPC)	Tel: +264 61 203 2406 Fax: +264 61 226631 Fax2mail : 0886606781 email: info.TIPC@mhss.gov.na

If you have any questions or require additional information, please contact Roche Products (Pty) Ltd as mentioned above.

Yours sincerely,

Dr Kgothatso Motumi
Management Centre Medical Head

Dr Clinton Rambanapasi
Snr Regulatory Pharmacist